Tags

Type your tag names separated by a space and hit enter

Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial.
Br J Nutr. 2012 Oct 28; 108(8):1443-54.BJ

Abstract

n-3 Long-chain PUFA (LC-PUFA) intake during infancy is important for neurodevelopment; however, previous studies of n-3 LC-PUFA supplementation have been inconclusive possibly due to an insufficient dose and limited methods of assessment. The present study aimed to evaluate the effects of direct supplementation with high-dose fish oil (FO) on infant neurodevelopmental outcomes and language. In the present randomised, double-blind, placebo-controlled trial, 420 healthy term infants were assigned to receive a DHA-enriched FO supplement (containing at least 250 mg DHA/d and 60 mg EPA/d) or a placebo (olive oil) from birth to 6 months. Assessment occurred at 18 months via the Bayley Scales of Infant and Toddler Development (3rd edition; BSID-III) and the Child Behavior Checklist. Language assessment occurred at 12 and 18 months via the Macarthur-Bates Communicative Development Inventory. The FO group had significantly higher erythrocyte DHA (P = 0·03) and plasma phospholipid DHA (P = 0·01) levels at 6 months of age relative to placebo. In a small subset analysis (about 40% of the total population), children in the FO group had significantly higher percentile ranks of both later developing gestures at 12 and 18 months (P = 0·007; P = 0·002, respectively) and the total number of gestures (P = 0·023; P = 0·006, respectively). There was no significant difference between the groups in the standard or composite scores of the BSID-III. The results suggest that improved postnatal n-3 LC-PUFA intake in the first 6 months of life using high-dose infant FO supplementation was not beneficial to global infant neurodevelopment. However, some indication of benefits to early communicative development was observed.

Authors+Show Affiliations

School of Paediatrics and Child Health, University of Western Australia, M561, 35 Stirling Highway, Crawley, 6009 WA, Australia. suzanne.meldrum@uwa.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22348468

Citation

Meldrum, Suzanne J., et al. "Effects of High-dose Fish Oil Supplementation During Early Infancy On Neurodevelopment and Language: a Randomised Controlled Trial." The British Journal of Nutrition, vol. 108, no. 8, 2012, pp. 1443-54.
Meldrum SJ, D'Vaz N, Simmer K, et al. Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial. Br J Nutr. 2012;108(8):1443-54.
Meldrum, S. J., D'Vaz, N., Simmer, K., Dunstan, J. A., Hird, K., & Prescott, S. L. (2012). Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial. The British Journal of Nutrition, 108(8), 1443-54. https://doi.org/10.1017/S0007114511006878
Meldrum SJ, et al. Effects of High-dose Fish Oil Supplementation During Early Infancy On Neurodevelopment and Language: a Randomised Controlled Trial. Br J Nutr. 2012 Oct 28;108(8):1443-54. PubMed PMID: 22348468.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial. AU - Meldrum,Suzanne J, AU - D'Vaz,Nina, AU - Simmer,Karen, AU - Dunstan,Janet A, AU - Hird,Kathryn, AU - Prescott,Susan L, Y1 - 2012/02/21/ PY - 2012/2/22/entrez PY - 2012/2/22/pubmed PY - 2012/12/27/medline SP - 1443 EP - 54 JF - The British journal of nutrition JO - Br J Nutr VL - 108 IS - 8 N2 - n-3 Long-chain PUFA (LC-PUFA) intake during infancy is important for neurodevelopment; however, previous studies of n-3 LC-PUFA supplementation have been inconclusive possibly due to an insufficient dose and limited methods of assessment. The present study aimed to evaluate the effects of direct supplementation with high-dose fish oil (FO) on infant neurodevelopmental outcomes and language. In the present randomised, double-blind, placebo-controlled trial, 420 healthy term infants were assigned to receive a DHA-enriched FO supplement (containing at least 250 mg DHA/d and 60 mg EPA/d) or a placebo (olive oil) from birth to 6 months. Assessment occurred at 18 months via the Bayley Scales of Infant and Toddler Development (3rd edition; BSID-III) and the Child Behavior Checklist. Language assessment occurred at 12 and 18 months via the Macarthur-Bates Communicative Development Inventory. The FO group had significantly higher erythrocyte DHA (P = 0·03) and plasma phospholipid DHA (P = 0·01) levels at 6 months of age relative to placebo. In a small subset analysis (about 40% of the total population), children in the FO group had significantly higher percentile ranks of both later developing gestures at 12 and 18 months (P = 0·007; P = 0·002, respectively) and the total number of gestures (P = 0·023; P = 0·006, respectively). There was no significant difference between the groups in the standard or composite scores of the BSID-III. The results suggest that improved postnatal n-3 LC-PUFA intake in the first 6 months of life using high-dose infant FO supplementation was not beneficial to global infant neurodevelopment. However, some indication of benefits to early communicative development was observed. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/22348468/Effects_of_high_dose_fish_oil_supplementation_during_early_infancy_on_neurodevelopment_and_language:_a_randomised_controlled_trial_ L2 - https://www.cambridge.org/core/product/identifier/S0007114511006878/type/journal_article DB - PRIME DP - Unbound Medicine ER -